Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Csenge Advisory Group

Csenge Advisory Group grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 23.1% in the second quarter, Holdings Channel reports. The institutional investor owned 3,402 shares of the pharmaceutical company’s stock after buying an additional 638 shares during the period. Csenge Advisory Group’s holdings in Vertex Pharmaceuticals were worth $1,595,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of VRTX. Founders Capital Management increased its holdings in shares of Vertex Pharmaceuticals by 50.0% in the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after purchasing an additional 25 shares in the last quarter. RDA Financial Network increased its holdings in shares of Vertex Pharmaceuticals by 201.0% in the 2nd quarter. RDA Financial Network now owns 6,869 shares of the pharmaceutical company’s stock valued at $3,220,000 after purchasing an additional 4,587 shares in the last quarter. Atwood & Palmer Inc. increased its holdings in shares of Vertex Pharmaceuticals by 0.3% in the 2nd quarter. Atwood & Palmer Inc. now owns 54,275 shares of the pharmaceutical company’s stock valued at $25,440,000 after purchasing an additional 142 shares in the last quarter. Anderson Hoagland & Co. increased its holdings in shares of Vertex Pharmaceuticals by 0.3% in the 2nd quarter. Anderson Hoagland & Co. now owns 21,236 shares of the pharmaceutical company’s stock valued at $10,320,000 after purchasing an additional 63 shares in the last quarter. Finally, CWM LLC increased its holdings in shares of Vertex Pharmaceuticals by 6.2% in the 2nd quarter. CWM LLC now owns 6,414 shares of the pharmaceutical company’s stock valued at $3,006,000 after purchasing an additional 374 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Activity

In related news, Director Bruce I. Sachs sold 7,073 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at approximately $17,920,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at approximately $20,320,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bruce I. Sachs sold 7,073 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the completion of the sale, the director now directly owns 40,000 shares of the company’s stock, valued at $17,920,000. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,703 shares of company stock valued at $26,615,855. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX traded up $0.07 during midday trading on Thursday, hitting $465.96. 1,544,997 shares of the stock traded hands, compared to its average volume of 1,225,676. Vertex Pharmaceuticals Incorporated has a 1-year low of $340.83 and a 1-year high of $510.64. The firm has a market capitalization of $120.26 billion, a PE ratio of 30.24 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. The business’s 50 day moving average price is $480.69 and its two-hundred day moving average price is $440.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The firm had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same period last year, the firm posted $3.53 EPS. The business’s revenue was up 6.1% compared to the same quarter last year. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Royal Bank of Canada lowered their price objective on shares of Vertex Pharmaceuticals from $424.00 to $421.00 and set a “sector perform” rating on the stock in a research note on Tuesday, June 11th. Canaccord Genuity Group raised their target price on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the stock a “sell” rating in a research report on Wednesday, July 31st. UBS Group cut their price target on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, July 26th. Finally, JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $505.00 to $510.00 and gave the company an “overweight” rating in a report on Monday. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $485.91.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.